Reduced kynurenine pathway metabolism and cytokine expression in the prefrontal cortex of depressed individuals

Journal of Psychiatry and Neuroscience

Volumn 41, Issue 6, 2016, Pages 386-394

  Clark, Sarah M ^a   Pocivavsek, Ana ^a   Nicholson, James D ^a   Notarangelo, Francesca M ^a   Langenberg, Patricia ^a   McMahon, Robert P ^a   Kleinman, Joel E ^b,c   Hyde, Thomas M ^b,c   Stiller, John ^a   Postolache, Teodor T ^a   Schwarcz, Robert ^a   Tonelli, Leonardo H ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; KYNURENINE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; MESSENGER RNA;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DEPRESSION; FEMALE; GAS CHROMATOGRAPHY; GEOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MIDDLE AGED; MOLECULAR PATHOLOGY; NEUROTRANSMISSION; PREFRONTAL CORTEX; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; YOUNG ADULT; METABOLISM; PATHOLOGY; POLYMERASE CHAIN REACTION;

ADULT; CYTOKINES; DEPRESSIVE DISORDER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KYNURENINE; MALE; POLYMERASE CHAIN REACTION; PREFRONTAL CORTEX; RNA, MESSENGER;

EID: 84992499908     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.150226     Document Type: Article

References (61)

1. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011;130: 226-38.
2. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012;37:137-62.
3. Miller AH, Haroon E, Raison CL, et al. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety 2013;30:297-306
4. Raison CL, Miller AH. Malaise, melancholia and madness: the evolutionary legacy of an inflammatory bias. Brain Behav Immun 2013; 31:1-8.
5. Elovainio M, Hurme M, Jokela M, et al. Indoleamine 2,3­­dioxygenase activation and depressive symptoms: results from the Young Finns Study. Psychosom Med 2012;74:675-81.
6. Gabbay V, Liebes L, Katz Y, et al. The kynurenine pathway in adolescent depression: preliminary findings from a proton MR spectroscopy study. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:37-44.
7. Kim H, Chen L, Lim G, et al. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J Clin Invest 2012;122:2940-54.
8. Maes M, Mihaylova I, Ruyter MD, et al. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression and other conditions characterized by tryptophan depletion induced by inflammation. Neuroendocrinol Lett 2007;28:826-31.
9. Müller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 2007;12:988-1000.
10. Raison CL, Dantzer R, Kelley KW, et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: elationship to CNS immune responses and depression. Mol Psychiatry 2010;15:393-403 10.1038/mp.2009.116.
11. Wichers MC, Koek GH, Robaeys G, et al. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005;10:538-44.
12. Moroni F, Cozzi A, Sili M, et al. Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm (Vienna) 2012;119:133-9.
13. Pocivavsek A, Wu HQ, Potter MC, et al. Fluctuations in endo­genous kynurenic acid control hippocampal glutamate and memory. Neuropsychopharmacology 2011;36:2357-67.
14. Schwarcz R, Bruno JP, Muchowski PJ, et al. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012;13:465-77.
15. Wu HQ, Pereira EF, Bruno JP, et al. The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J Mol Neurosci 2010;40:204-10.
16. Zarate C, Duman RS, Liu G, et al. New paradigms for treatment-resistant depression. Ann N Y Acad Sci 2013;1292:21-31.
17. McNutt MD, Liu S, Manatunga A, et al. Neurobehavioral effects of interferon-alpha in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine. Neuropsychopharmacology 2012; 37:1444-54.
18. Capuron L, Neurauter G, Musselman DL, et al. Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry 2003;54:906-14.
19. Dantzer R, Wollman EE, Yirmiya R. Cytokines and depression: an update. Brain Behav Immun 2002;16:501-2.
20. Pollmächer T, Haack M, Schuld A, et al. Low levels of circulating inflammatory cytokines — Do they affect human brain functions? Brain Behav Immun 2002;16:525-32.
21. Erhardt S, Lim CK, Linderholm KR, et al. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology 2013;38:743-52.
22. Gabbay V, Ely BA, Babb J, et al. The possible role of the kynurenine pathway in anhedonia in adolescents. J Neural Transm (Vienna) 2012;119:253-60.
23. Gabbay V, Klein RG, Katz Y, et al. The possible role of the kynurenine pathway in adolescent depression with melancholic features. J Child Psychol Psychiatry 2010;51:935-43.
24. Sublette ME, Postolache TT. Neuroinflammation and depression: the role of indoleamine 2,3-dioxygenase (IDO) as a molecular pathway. Psychosom Med 2012;74:668-72.
25. Hughes MM, Carballedo A, McLoughlin DM, et al. Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation. Brain Behav Immun 2012;26:979-87.
26. Quak J, Doornbos B, Roest AM, et al. Does tryptophan degradation along the kynurenine pathway mediate the association between pro-inflammatory immune activity and depressive symptoms? Psychoneuroendocrinology 2014;45:202-10.
27. Bay-Richter C, Linderholm KR, Lim CK, et al. A role for inflammatory metabolites as modulators of the glutamate N-methyl-d-aspartate receptor in depression and suicidality. Brain Behav Immun 2015;43:110-7.
28. Miller CL, Llenos IC, Cwik M, et al. Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. Neurochem Int 2008;52:1297-303.
29. Miller CL, Llenos IC, Dulay JR, et al. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 2006;1073-1074:25-37.
30. Steiner J, Walter M, Gos T, et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: Evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation 2011;8:94.
31. Drevets WC. Orbitofrontal cortex function and structure in depression. Ann N Y Acad Sci 2007;1121:499-527.
32. Koenigs M, Grafman J. The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav Brain Res 2009;201:239-43.
33. Price JL, Drevets WC. Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn Sci 2012;16:61-71.
34. Neumeister A, Nugent AC, Waldeck T, et al. Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry 2004;61:765-73.
35. Mann JJ. Neurobiology of suicidal behaviour. Nat Rev Neurosci 2003;4:819-28.
36. Arango V, Underwood MD, Mann JJ. Postmortem findings in suicide victims. Implications for in vivo imaging studies. Ann N Y Acad Sci 1997;836:269-87.
37. Underwood MD, Kassir SA, Bakalian MJ, et al. Neuron density and serotonin receptor binding in prefrontal cortex in suicide. Int J Neuropsychopharmacol 2012;15:435-47.
38. Tonelli LH, Stiller J, Rujescu D, et al. Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta psychiatrica Scandinavica 2008;117:198-206.
39. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101-8.
40. Notarangelo FM, Wu HQ, Macherone A, et al. Gas chromatography/tandem mass spectrometry detection of extracellular kynurenine and related metabolites in normal and lesioned rat brain. Anal Biochem 2012;421:573-81.
41. Guidetti P, Hoffman GE, Melendez-Ferro M, et al. Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry. Glia 2007;55:78-92.
42. Benjamini YH. Controlling the false discovery rate: a new and powerful approach to multiple testing. J R Stat Soc Ser A Stat Soc 1995;57:1289-300.
43. van Donkelaar EL, Blokland A, Ferrington L, et al. Mechanism of acute tryptophan depletion: Is it only serotonin? Mol Psychiatry 2011;16:695-713.
44. Kennedy PJ, Allen AP, O’Neill A, et al. Acute tryptophan depletion reduces kynurenine levels: implications for treatment of impaired visuospatial memory performance in irritable bowel syndrome. Psychopharmacology (Berl) 2015;232:1357-71.
45. Sublette ME, Galfalvy HC, Fuchs D, et al. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav Immun 2011;25:1272-8.
46. Dahl J, Andreassen OA, Verkerk R, et al. Ongoing episode of major depressive disorder is not associated with elevated plasma levels of kynurenine pathway markers. Psychoneuroendocrinology 2015;56:12-22.
47. Savitz J, Drevets WC, Wurfel BE, et al. Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder. Brain Behav Immun 2015; 46:55-9.
48. Busse M, Busse S, Myint AM, et al. Decreased quinolinic acid in the hippocampus of depressive patients: Evidence for local antiinflammatory and neuroprotective responses? Eur Arch Psychiatry Clin Neurosci 2015;265:321-9.
49. Dean B, Gibbons AS, Tawadros N, et al. Different changes in cortical tumor necrosis factor-alpha-related pathways in schizophrenia and mood disorders. Mol Psychiatry 2013;18:767-73.
50. Dean B, Tawadros N, Scarr E, et al. Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. J Affect Disord 2010;120:245-8.
51. Pandey GN, Rizavi HS, Ren X, et al. Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J Psychiatr Res 2012;46:57-63.
52. Wang SS, Kamphuis W, Huitinga I, et al. Gene expression analysis in the human hypothalamus in depression by laser micro­ dissection and real-time PCR: the presence of multiple receptor imbalances. Mol Psychiatry 2008;13:786-99.
53. Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 2011;16:751-62.
54. Cuijpers P, de Graaf R, van Dorsselaer S. Minor depression: risk profiles, functional disability, health care use and risk of developing major depression. J Affect Disord 2004;79:71-9.
55. Setiawan E, Wilson AA, Mizrahi R, et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 2015;72:268-75.
56. Kreisel T, Frank MG, Licht T, et al. Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Mol Psychiatry 2014;19:699-709.
57. Schnieder TP, Trencevska I, Rosoklija G, et al. Microglia of prefrontal white matter in suicide. J Neuropathol Exp Neurol 2014; 73:880-90.
58. Torres-Platas SG, Cruceanu C, Chen GG, et al. Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides. Brain Behav Immun 2014;42:50-9.
59. Brustolim D, Ribeiro-dos-Santos R, Kast RE, et al. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol 2006;6:903-7.
60. Hwang J, Zheng LT, Ock J, et al. Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants. Neuropharmacology 2008;55:826-34.
61. Kubera M, Lin AH, Kenis G, et al. Anti-Inflammatory effects of antide­pressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 2001;21:199-206.